According to the latest status from September 2024, Halozyme Therapeutics paid a total of 0 USD per share in dividends within the last 12 months. With the current Halozyme Therapeutics price of 59.39 USD, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.
| = |
A dividend is paid times per year. Last year, the payout months were and .
| Paydate | Dividend |
|---|
Halozyme Therapeutics has been increasing the dividend for 0 years.
Over the past 10 years, Halozyme Therapeutics has increased it by an annual 0 %.
Over a five-year period, the distribution increased by 0%.
Analysts expect a Dividend Cut of -100% for the current fiscal year.
Halozyme Therapeutics’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.
Examining Halozyme Therapeutics's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.
Halozyme Therapeutics's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.
Changes in Halozyme Therapeutics’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.
Over the past 12 months, Halozyme Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Halozyme Therapeutics is expected to pay a dividend of 0 USD.
The current dividend yield of Halozyme Therapeutics is .
Halozyme Therapeutics pays a quarterly dividend. This is distributed in the months of .
Halozyme Therapeutics paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
Halozyme Therapeutics is assigned to the 'Health' sector.
To receive the latest dividend of Halozyme Therapeutics from 9/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.
The last dividend was paid out on 9/13/2024.
In the year 2023, Halozyme Therapeutics distributed 0 USD as dividends.
The dividends of Halozyme Therapeutics are distributed in USD.
Our stock analysis for Halozyme Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Halozyme Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
